Category Archives: IHC

HER2-LOW EDUCATIONAL WEB-PORTAL

This day's posts Posted on

This project is sponsored by IQN Path and provided by the UK NEQAS ICC & ISH. The results of the DESTINY-Breast 04 phase-3 clinical trial provided evidence that HER2-Low expressing breast cancer responded to treatment using the antibody-drug conjugate. trastuzumab deruxtecan (T-DXd) therapy [1] . As a result of the trial’s findings, the FDA approved read more…

Quality Assurance for Clinical Immunohistochemistry

This day's posts Posted on

IQN Path and the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) have put together a 4-part series on Quality Assurance for Clinical Immunohistochemistry. “Evolution of Quality Assurance for Clinical Immunohistochemistry (IHC) in the Era of Precision Medicine” from the lead author Emina Torlakovic. –      Part 1: Fit-for-purpose Approach to Classification of Clinical IHC Biomarkers –      read more…

Successful meeting of the In-Situ Methods Working Group

This day's posts Posted on

On Sunday 25th September, IQN Path held another successful working group meeting of the In-Situ Methods Working Group. Prof Mogens Vyberg and Dr Emina Torlakovic gave excellent presentations on the challenges and importance of quality in immunohistochemistry (IHC) testing with presentations on positive and negative controls for IHC and an overview of the key concepts read more…

IQN Path teams up with LMP pathologist to standardize immunohistochemistry terminology

This day's posts Posted on

IQN Path, represented by the executive director, Dr Jacqueline Hall, has been in collaboration with Dr. Emina Torlakovic Laboratory Medicine Program (LMP) and Canadian Immunohistochemsitry Quality Control (CIQC) an External Quality Assessment (EQA) provider to standardize a terminology and framework for quality in immunohistochemistry (IHC). Dr. Emina Torlakovic, hematopathologist, immunohistochemistry lab director at LMP and read more…